Literature DB >> 7668038

A single administration of tetanus toxoid in biodegradable microspheres elicits T cell and antibody responses similar or superior to those obtained with aluminum hydroxide.

Y Men1, C Thomasin, H P Merkle, B Gander, G Corradin.   

Abstract

The use of biodegradable polymer microspheres as a single dose vaccine delivery system was investigated by using tetanus toxoid (TT). In order to compare the immunogenicity of TT-microspheres (TT-MS) with aluminum hydroxide (alum)-based TT, BALB/c mice were immunized with TT in different formulations including individual or mixtures of MS and TT-alum. All TT-MS formulations elicited high proliferative and antibody responses comparable to those obtained with TT-alum formulation. Antibody levels remained elevated over a long period of time. Certain individual MS preparations elicited lower antibody titers than the MS mixtures. More importantly, the proliferative and antibody responses induced by a single injection of three TT-MS mixtures with different particle sizes and degradation rates were similar to those obtained with three injections of TT-alum. In addition, TT-MS induce similar isotypesubclass antibodies to those TT-alum induced. These results raise the possibility to obtain optimal and long-lasting immune responses by single administration of the three TT-MS mixture formulations alone.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7668038     DOI: 10.1016/0264-410x(94)00046-p

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  25 in total

1.  Phase I malaria vaccine trial with a long synthetic peptide derived from the merozoite surface protein 3 antigen.

Authors:  Régine Audran; Michel Cachat; Floriana Lurati; Soe Soe; Odile Leroy; Giampietro Corradin; Pierre Druilhe; François Spertini
Journal:  Infect Immun       Date:  2005-12       Impact factor: 3.441

2.  Improving stability and release kinetics of microencapsulated tetanus toxoid by co-encapsulation of additives.

Authors:  P Johansen; Y Men; R Audran; G Corradin; H P Merkle; B Gander
Journal:  Pharm Res       Date:  1998-07       Impact factor: 4.200

3.  Biodegradable particles as vaccine delivery systems: size matters.

Authors:  Vijaya B Joshi; Sean M Geary; Aliasger K Salem
Journal:  AAPS J       Date:  2012-10-10       Impact factor: 4.009

4.  A novel system based on a poloxamer/PLGA blend as a tetanus toxoid delivery vehicle.

Authors:  M Tobío; J Nolley; Y Guo; J McIver; M J Alonso
Journal:  Pharm Res       Date:  1999-05       Impact factor: 4.200

5.  Oral Biologic Delivery: Advances Toward Oral Subunit, DNA, and mRNA Vaccines and the Potential for Mass Vaccination During Pandemics.

Authors:  Jacob William Coffey; Gaurav Das Gaiha; Giovanni Traverso
Journal:  Annu Rev Pharmacol Toxicol       Date:  2020-08-31       Impact factor: 13.820

6.  Protein encapsulation in and release from monodisperse double-wall polymer microspheres.

Authors:  Yujie Xia; Qingxing Xu; Chi-Hwa Wang; Daniel W Pack
Journal:  J Pharm Sci       Date:  2013-03-25       Impact factor: 3.534

7.  PLG microsphere size controls drug release rate through several competing factors.

Authors:  Cory Berkland; Kyekyoon Kim; Daniel W Pack
Journal:  Pharm Res       Date:  2003-07       Impact factor: 4.200

8.  Enhanced immunogenicity of microencapsulated tetanus toxoid with stabilizing agents.

Authors:  R Audran; Y Men; P Johansen; B Gander; G Corradin
Journal:  Pharm Res       Date:  1998-07       Impact factor: 4.200

Review 9.  Vaccine adjuvants: current challenges and future approaches.

Authors:  Jennifer H Wilson-Welder; Maria P Torres; Matt J Kipper; Surya K Mallapragada; Michael J Wannemuehler; Balaji Narasimhan
Journal:  J Pharm Sci       Date:  2009-04       Impact factor: 3.534

10.  Tetanus toxoids loaded glucomannosylated chitosan based nanohoming vaccine adjuvant with improved oral stability and immunostimulatory response.

Authors:  Harshad Harde; Ashish Kumar Agrawal; Sanyog Jain
Journal:  Pharm Res       Date:  2014-07-17       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.